Trial Information
DNA Chip Based Prognosis of Lung Cancer
Inclusion Criteria:
1. A histological diagnosis of primary NSCLC stage Ia
2. Surgical removal of the tumor
3. Age between 18 and 75 years
4. Ability to understand and the willingness to sign a written informed consent
document.
Exclusion Criteria:
1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC
stage Ib-IV after surgery.
2. Adjuvant treatment with chemotherapy.
3. Prior history of cancer in the past 5 years or breast cancer at any time.
4. Life expectancy less than 3 years in the opinion of the investigator due to
concurrent illnesses.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Steen Knudsen, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
Medical Prognosis Institute (MPI)
Authority:
United States: Institutional Review Board
Study ID:
MPI-1001
NCT ID:
NCT00973427
Start Date:
June 2008
Completion Date:
May 2012
Related Keywords:
- Carcinoma, Non-Small-Cell Lung
- NSCLC
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
University of Alabama |
Birmingham, Alabama |
Roswell Park Cancer Institute |
Buffalo, New York 14263 |